Clinical trial · no report yet · Phase 3
AMBRE
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
- NCT04158362 ↗
- Active not recruiting
- UNICANCER
- 12 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 7 | |
| YouTube | 2 | |
| Podcasts | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemotherapy to Standard Combination of Endocrine Therapy With Abemaciclib as Initial Metastatic Treatment Among Patients With Visceral Metastasis of ER+ HER2-breast Cancer, High Burden Disease
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Cancer Metastatic
- Interventions
- Paclitaxel injection; Capecitabine tablets; Letrozole 2.5mg; Anastrozole 1mg; Fulvestrant Prefilled Syringe; Abemaciclib
- Arms
- Standard Chemotherapy regimen · Experimental
- Standard Endocrine therapy (ET) regimen + Abemaciclib · Experimental
- Enrollment
- 180
- Primary outcomes
- Progression-free survival (PFS)
- Sponsor
- UNICANCER
- Start
- Jun 11, 2020
- Primary completion
- Apr 30, 2025
- Results posted
- No
- Registry record
- NCT04158362 · updated Jul 22, 2026